title: Effect of dexmedetomidine premedication on the intraocular pressure changes after succinylcholine and intubation.
abstract: BACKGROUND
  Succinylcholine is still recommended for some situations in open globe injuries. However, the use of succinylcholine is associated with an increase in intraocular pressure (IOP). This may be deleterious in open globe injuries. No method has previously been shown to abolish completely this rise in the IOP. We investigated whether dexmedetomidine, an alpha-2 agonist, could attenuate this increase in the IOP after succinylcholine and intubation.
  
  
  METHODS
  Forty patients with no pre-existing eye disease undergoing general anaesthesia were randomly premedicated by i.v. dexmedetomidine 0.6 microg kg(-1), or saline. Heart rate (HR), mean arterial pressure (MAP), and IOP (using Schioetz tonometer) were measured before, after the premedication, after thiopental, after succinylcholine, immediately after intubation, and then every 2 min for 6 min.
  
  
  RESULTS
  Succinylcholine and intubation increased IOP in both groups. However, in the dexmedetomidine group, the IOP rise was not different from the baseline value (P=0.65) and was significantly lower than in the saline group (P=0.003). After intubation, the MAP in the control group was higher than that in the dexmedetomidine group (P=0.041) and exceeded the baseline value (P<0.001). The HR also showed less fluctuation in the dexmedetomidine group than in the saline group.
  
  
  CONCLUSIONS
  We conclude that dexmedetomidine could be a beneficial premedication in open globe injuries.
authors.affiliation: Department of Anaesthesiology, Faculty of Medicine, King Faisal University, Saudi Arabia. hany_mowafi@hotmail.com
authors.forename: H A
authors.initials: HA
authors.lastname: Mowafi
authors.forename: N
authors.initials: N
authors.lastname: Aldossary
authors.forename: S A
authors.initials: SA
authors.lastname: Ismail
authors.forename: J
authors.initials: J
authors.lastname: Alqahtani
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D020927:Dexmedetomidine / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology / Q000627:therapeutic use; D007429:Intraocular Pressure / Q000187:drug effects; D007442:Intubation, Intratracheal / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D009798:Ocular Hypertension / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D011292:Premedication / Q000379:methods; D013390:Succinylcholine / Q000009:adverse effects* / Q000037:antagonists & inhibitors
chemical_list: D000316:Adrenergic alpha-Agonists; D006993:Hypnotics and Sedatives; D009467:Neuromuscular Depolarizing Agents; D020927:Dexmedetomidine; D013390:Succinylcholine